Clinical Trial Update: A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) [Phase 2]

View source ↗

Summary

This Phase II study evaluates single-agent Brentuximab Vedotin in relapsed/refractory CD30-low mature T-cell lymphomas; the trial has completed and results are …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioimmunoblastic T-cell Lymphoma
• Enteropathy-associated T-cell Lymphoma
• Hepatosplenic T-cell Lymphoma
• Natural Killer T-cell Lymphoma
• Peripheral T-cell Lymphoma
• T-cell Leukemia Lymphoma

Drugs mentioned

• Adcetris (brentuximab vedotin) (brentuximab vedotin)

Snippet

Sponsor: Deepa Jagadeesh | Conditions: T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2025-11-21